Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... a Florida State University research team has led to ... emit white light, and convert photon energy directly to ... butterfly. , Biwu Ma, associate professor in the Department ... of Engineering, created the molecule in a lab about ... his creation has many other unique capabilities. , For ...
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
(Date:8/27/2014)... MSC , a healthcare performance improvement company advancing clinical ... Mary Beth Loesch to President and CEO. ... companies for rapid growth and market expansion, Loesch joined ... Development and Healthcare. In that role, she oversaw MSC,s ... corporate strategy and marketing. Previously, Loesch served as Senior ...
Breaking Biology Technology:Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2
... ,S-HERTOGENBOSCH, The Netherlands , April 28, 2010 , Pepscan, ... for the generation of immune therapeutics, today,announced that it reached a ... Under the terms of the,agreement Pepscan will receive an undisclosed cash ... , , ...
... The Netherlands , April 27, 2010 Immunovo,BV, a new ... insights in oncology to develop novel,therapeutics, secures seed funding from Dutch venture ... ... - Immunovo BV, a new,biotechnology company developing a novel technology platform for ...
... April 27 The Johns Hopkins University School of Medicine ... collaborative program to advance the development and use of stem cells in therapies ... train researchers to use stem cells and foster joint research projects. , ... The collaborative program will encompass training for ...
Cached Biology Technology:Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 2Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio 3Immunovo BV- A New Biotechnology Company is Announced 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 2The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 3The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 4The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research 5
(Date:8/28/2014)... million kilometres of new roads will be built worldwide ... Earth,s last wildernesses, where they bring an influx of ... an ambitious study has created a ,global roadmap, for ... balance the competing demands of development and environmental protection. ... that estimates that natural importance of ecosystems and a ...
(Date:8/28/2014)... California, and Alaska totaled 515 million board feet in ... of more than 10 percent compared to the first ... Research Station reported today. During this same period, West ... million board feet. , The total value of these ... $390 million in the same quarter, while the total ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3West coast log exports up, lumber exports down in second quarter of 2014 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3
... could become even more prevalent and destructive as climate change ... more than 150 years. Writing in the journal ... study say that non-native plants, and especially invasive species, appear ... able to adjust the timing of annual activities like flowering ...
... Charles Drew University of Medicine and Science is investigating the ... therapy for cancer. Dr. Mamdooh Ghoneum presented his findings ... Mechanism," sponsored by the American Association for Cancer Research (AACR) ... "The central focus of the meeting is cell death ...
... A 60-million-year-old relative of crocodiles described this week by ... Vertebrate Paleontology was likely a food source for ... Working with scientists from the Smithsonian Tropical Research ... Natural History on the UF campus found fossils of ...
Cached Biology News:Invasive plants are beneficiaries of climate change in Thoreau's woods 2Charles Drew cancer studies with yeast yield excellent results 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 2UF researchers: Ancient crocodile relative likely food source for Titanoboa 3